Combined pharmacotherapy in pediatric psychopharmacology: Friend or Foe?

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 5, 2009, Pages 483-484

  Wilens, Timothy E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATOMOXETINE; CENTRAL STIMULANT AGENT; GUANFACINE; METHYLPHENIDATE; NEUROLEPTIC AGENT;

ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CHILD; CLINICAL TRIAL; COMORBIDITY; DISRUPTIVE BEHAVIOR; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; MONOTHERAPY; MOOD DISORDER; PSYCHOPHARMACOLOGY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DRUG THERAPY, COMBINATION; HUMANS; MOOD DISORDERS; PSYCHOTROPIC DRUGS;

EID: 70449087455     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2009.19501     Document Type: Editorial

References (3)

1. Meltzer HY. Psychopharmacology. The Third Generation of Progress. New York: Raven Press, 1987.
2. Raghavan R and McMillen JC. Use of multiple psychotropic medications among adolescents aging out of foster care. Psychiatr Serv 59:1052-1055, 2008.
3. Wilens TE, Spencer TJ, Biederman J, Wozniak J, and Connor DE. Combined pharmacotherapy: An emerging trend in pediatric psychopharmacology. J Am Acad Child Adolesc Psychiatry 34:110-112, 1995.